1. Home
  2. VRAX vs ALZN Comparison

VRAX vs ALZN Comparison

Compare VRAX & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VRAX
  • ALZN
  • Stock Information
  • Founded
  • VRAX 2013
  • ALZN 2016
  • Country
  • VRAX United Kingdom
  • ALZN United States
  • Employees
  • VRAX N/A
  • ALZN N/A
  • Industry
  • VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • ALZN Medicinal Chemicals and Botanical Products
  • Sector
  • VRAX Health Care
  • ALZN Health Care
  • Exchange
  • VRAX Nasdaq
  • ALZN Nasdaq
  • Market Cap
  • VRAX 4.7M
  • ALZN 4.5M
  • IPO Year
  • VRAX 2022
  • ALZN 2021
  • Fundamental
  • Price
  • VRAX $0.98
  • ALZN $3.62
  • Analyst Decision
  • VRAX Strong Buy
  • ALZN Strong Buy
  • Analyst Count
  • VRAX 1
  • ALZN 1
  • Target Price
  • VRAX $3.00
  • ALZN $180.00
  • AVG Volume (30 Days)
  • VRAX 67.1K
  • ALZN 4.6M
  • Earning Date
  • VRAX 02-05-2025
  • ALZN 07-29-2025
  • Dividend Yield
  • VRAX N/A
  • ALZN N/A
  • EPS Growth
  • VRAX N/A
  • ALZN N/A
  • EPS
  • VRAX N/A
  • ALZN N/A
  • Revenue
  • VRAX $84,872.00
  • ALZN N/A
  • Revenue This Year
  • VRAX $5,169.18
  • ALZN $322.64
  • Revenue Next Year
  • VRAX $66.97
  • ALZN N/A
  • P/E Ratio
  • VRAX N/A
  • ALZN N/A
  • Revenue Growth
  • VRAX 7.03
  • ALZN N/A
  • 52 Week Low
  • VRAX $0.82
  • ALZN $3.06
  • 52 Week High
  • VRAX $9.00
  • ALZN $135.54
  • Technical
  • Relative Strength Index (RSI)
  • VRAX 44.60
  • ALZN 42.05
  • Support Level
  • VRAX $0.91
  • ALZN $3.55
  • Resistance Level
  • VRAX $1.03
  • ALZN $4.30
  • Average True Range (ATR)
  • VRAX 0.08
  • ALZN 0.58
  • MACD
  • VRAX -0.00
  • ALZN 0.11
  • Stochastic Oscillator
  • VRAX 24.46
  • ALZN 7.44

About VRAX Virax Biolabs Group Limited

Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.

About ALZN Alzamend Neuro Inc.

Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.

Share on Social Networks: